Kanjinti

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Kanjinti treats breast and stomach cancer. HER2 test determines if your cancer is HER2-positive before taking this medication. Benefit has only been shown in patients whose tumors are HER2+.

Kanjinti Overview

Reviewed: July 24, 2019
Updated: 

Kanjinti is a prescription medication used to treat breast cancer and stomach cancer. It may be used alone or in combination with other medications. Kanjinti belongs to a group of drugs called monoclonal antibodies, which help stop the growth of cancer cells.

This medication comes in an injectable form and is given into the vein (IV) by a healthcare provider once every week or once every 3 weeks.

Common side effects of Kanjinti include fever, nausea, and vomiting.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Kanjinti Drug Class

Back to Top

Kanjinti is part of the drug class:

Kanjinti FDA Warning

Back to Top

WARNING: CARDIOMYOPATHY, INFUSION REACTIONS, EMBRYO-FETAL TOXICITY, and PULMONARY TOXICITY

Cardiomyopathy

Trastuzumab products administration can result in sub-clinical and clinical cardiac failure. The incidence and severity was highest in patients receiving trastuzumab with anthracycline-containing chemotherapy regimens.

Evaluate left ventricular function in all patients prior to and during treatment with KANJINTI. Discontinue KANJINTI treatment in patients receiving adjuvant therapy and withhold KANJINTI in patients with metastatic disease for clinically significant decrease in left ventricular function [see Dosage and Administration and Warnings and Precautions.

Infusion Reactions; Pulmonary Toxicity

Trastuzumab products administration can result in serious and fatal infusion reactions and pulmonary toxicity. Symptoms usually occur during or within 24 hours of administration. Interrupt KANJINTI infusion for dyspnea or clinically significant hypotension. Monitor patients until symptoms completely resolve. Discontinue KANJINTI for anaphylaxis, angioedema, interstitial pneumonitis, or acute respiratory distress syndrome [see Warnings and Precautions.

Embryo-Fetal Toxicity

Exposure to trastuzumab products during pregnancy can result in oligohydramnios and oligohydramnios sequence manifesting as pulmonary hypoplasia, skeletal abnormalities, and neonatal death. Advise patients of these risks and the need for effective contraception
[see Warnings and Precautions (5.3) and Use in Specific Populations.